Unrelated HLA-matched donor marrow transplantation for one case of myelodysplastic syndrome.
- Author:
Chun-Ji GAO
1
;
Wan-Ming DA
;
Bo-Long ZHANG
;
Xiao-Ping HAN
;
Hai-Yan ZHU
;
Hai-Jie JIN
;
Yu JING
;
Wen-Rong HUANG
Author Information
1. Department of Hematology, General Hospital PLA, Beijing 100853, China. gaochunji@hotmail.com
- Publication Type:Case Reports
- MeSH:
Adult;
Bone Marrow Transplantation;
Follow-Up Studies;
Graft vs Host Disease;
etiology;
Hematopoiesis;
Histocompatibility Testing;
Humans;
Male;
Myelodysplastic Syndromes;
therapy
- From:
Journal of Experimental Hematology
2004;12(3):378-380
- CountryChina
- Language:Chinese
-
Abstract:
To explore feasibility and efficacy of unrelated HLA matched donor marrow transplantation in treatment of myelodysplastic syndrome, one case (male, 31 years old) of myelodysplastic syndrome-refractory cytopenia with multilineage dysplasia (MDS-RCMD) has been received unrelated HLA-matched donor transplantation. Busulfan, cyclophosphamide, Ara-C, MeCCNU and antithymocyte globulin (ATG) were used for preparative regimen. Mycophenolate mofetile, cyclosporin A and short-term methotrexate were used for graft-versus-host disease prophylaxis. The results showed that neutrophil of > 0.5 x 10(9)/L, platelet of 58 x 10(9)/L and hemoglobin of 114 g/L were observed at 10, 20 days and 3 months respectively post transplantation. Disease-free survival without GVHD was 9 months. In conclusion, unrelated HLA matched donor marrow transplantation is an effective approach for treatment of patients with MDS.
